Mangoceuticals advances in H1N1 and H5N1 studies

DALLAS - Mangoceuticals, Inc. (NASDAQ: MGRX), a telemedicine company focused on men’s wellness products with a market capitalization of $8.12 million, has announced progress in its H1N1 efficacy study and the initiation of a concurrent study on H5N1, both involving its patented respiratory illness prevention technology. The company, which has achieved impressive gross profit margins of 58.6% according to InvestingPro data, is conducting these studies through Vipragen Biosciences in Mysuru, India, in collaboration with Intramont Technologies, Inc.

The H1N1 study has yielded promising preliminary results, showing a significant reduction in viral load, which has propelled the company to proceed to the next phase of research. Concurrently, the company is structuring a cohort to evaluate the same technology against the H5N1 virus, commonly known as Avian Influenza.

Jacob Cohen, Founder and CEO of Mangoceuticals, expressed confidence in the potential of their platform, stating that the inclusion of H5N1 research underscores their commitment to addressing global respiratory illnesses. The company has shown strong momentum with a 30.99% year-to-date return and 52.2% revenue growth in the last twelve months. Dr. Douglas Christianson, the company’s Director of Medical (TASE:PMCN) Research and Product Innovation, emphasized the versatility of their technology and their dedication to innovation in the face of evolving viral threats.

The studies utilize Mangoceuticals’ proprietary formulation of advanced polyphenol and zinc chemistry. Final results of the studies will be disclosed after completion and securing intellectual property protections.

Mangoceuticals, also known as MangoRx, has identified men’s wellness telemedicine services as a growing sector, offering products and services for erectile dysfunction, hair growth, hormone replacement therapies, and weight management. The company’s telemedicine platform allows for a streamlined consumer experience, with prescription requests reviewed by physicians and fulfilled by the company’s partner compounding pharmacy.

This announcement is based on a press release statement from Mangoceuticals, Inc. and does not include any promotional content or subjective assessment. While the company shows promising operational metrics, InvestingPro analysis reveals challenges in cash burn rate and profitability. The company’s forward-looking statements are subject to various risks and uncertainties, and there is no assurance that the anticipated results will be achieved. For deeper insights into MGRX’s financial health and 12+ additional ProTips, consider subscribing to InvestingPro.

In other recent news, Mangoceuticals, a Texas-based health services company, has made noteworthy changes to its corporate structure and operations. The company introduced a new class of Series A Super Majority Voting Preferred Stock, granting substantial voting rights to the holders and significantly altering the balance of power within the company’s shareholder base. The anticipated recipient of these shares is Jacob Cohen, the CEO of Mangoceuticals.

In addition, Mangoceuticals entered into a new service agreement with Greentree Financial Group, Inc., under which the company will issue 40,000 shares of its restricted common stock to Greentree. The company also disclosed the sale of 75,000 shares of common stock to Platinum Point Capital.

Furthermore, Mangoceuticals is investigating potential stock manipulation following a reverse stock split, in response to abnormal trading patterns and a significant increase in shareholder accounts.

Also, Eugene M. Johnston, the Chief Financial Officer of Mangoceuticals, entered a Consulting Agreement with the company, under which he will receive a monthly payment and a grant of 25,000 shares of Mangoceuticals common stock. These developments are part of the company’s recent activities, as reported in various filings with the Securities and Exchange Commission and press releases.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.